Sensorion reports full-year 2019 financial results and business update Solid EUR30m cash position at year end and runway increased to beginning of Q3 2021. Read
(WorldNews France)

Press release Sensorion reports full-year 2019 financial results and business update Solid EUR30m cash position at year end and runway increased to beginning of Q3 2021 PhII trial with SENS-401 in SSNHL started it will include patients from the French Armed Forces; SENS-401 received an IND in the US Two preclinical Gene Therapy programs targeting Otoferlin and Usher Type 1 were initiated as part of the framework agreement signed with Institut Pasteur Executive and scientific teams have been significantly strengthened in 2019 and early 2020 with the arrival of key renowned talents Significant financing milestones were achieved with EUR38m raised with leading biotech investors and Chinese...